iRadimed Q4 revenue $14.9M (+25% YoY); declares special $1.05 dividend; FY23 guidance $61-63M

IRADIMED CORP

2022-FY EPS reported $1.02 revenue$53,303,145

Q4 2022 revenue $14.9M (vs $11.9M Q4 2021); GAAP diluted EPS $0.29; non-GAAP diluted EPS $0.32.
Full-year 2022 revenue $53.3M (vs $41.8M FY2021); GAAP EPS $1.02; non-GAAP EPS $1.10.
Board declared special cash dividend of $1.05/share, payable Feb 21, 2023 to holders of record Feb 13, 2023.
FY 2023 guidance: revenue $61-63M, GAAP EPS $1.10-1.20, non-GAAP EPS $1.23-1.34; Q1 2023 revenue $14.6-14.9M.
Cash and equivalents $57.9M, no debt; gross margin 77.4% for full year 2022 (up from 76.6%).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IRADIMED CORP reported the twelve months ended December 31, 2022 results: revenue $53.3 million, net income $12.8 million, EPS $1.02 per diluted share. Guidance initiated.

Period: the twelve months ended December 31, 2022
Revenue: $53.3 million
Net income: $12.8 million
EPS: $1.02 per diluted share
Guidance: initiated
Result: reported results

Exact text from the filing

For the twelve months ended December 31, 2022, the Company reported revenue of $53.3 million compared to $41.8 million for the same period in 2021. Net income was $12.8 million, or $1.02 per diluted share, compared to $9.3 million, or $0.74 per diluted share, for the same period in 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IRADIMED CORP reported full year 2023 results: revenue $61 million to $63 million, EPS $1.10 to $1.20 per diluted share (GAAP). Guidance initiated.

Period: full year 2023
Revenue: $61 million to $63 million
EPS: $1.10 to $1.20 per diluted share (GAAP)
Guidance: initiated
Result: guidance update

Exact text from the filing

For the full year 2023, the Company expects to report revenue of $61 million to $63 million, GAAP diluted earnings per share of $1.10 to $1.20, and non-GAAP diluted earnings per share of $1.23 to $1.34.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IRADIMED CORP reported first quarter of 2023 results: revenue $14.6 million to $14.9 million, EPS $0.23 to $0.25 per diluted share (GAAP). Guidance initiated.

Period: first quarter of 2023
Revenue: $14.6 million to $14.9 million
EPS: $0.23 to $0.25 per diluted share (GAAP)
Guidance: initiated
Result: guidance update

Exact text from the filing

For the first quarter of 2023, the Company expects to report revenue of $14.6 million to $14.9 million, GAAP diluted earnings per share of $0.23 to $0.25, and non-GAAP diluted earnings per share of $0.26 to $0.28.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IRADIMED CORP reported the fourth quarter ended December 31, 2022 results: revenue $14.9 million, net income $3.7 million, EPS $0.29 per diluted share. Guidance initiated.

Period: the fourth quarter ended December 31, 2022
Revenue: $14.9 million
Net income: $3.7 million
EPS: $0.29 per diluted share
Guidance: initiated
Result: reported results

Exact text from the filing

For the fourth quarter ended December 31, 2022, the Company reported revenue of $14.9 million compared to $11.9 million for the fourth quarter of 2021. Net income was $3.7 million, or $0.29 per diluted share, compared to $3.9 million, or $0.31 per diluted share, for the fourth quarter of 2021.

View on SEC.gov

Browse all earnings releases →

IRADIMED CORP filing history →

Source: SEC EDGAR

accession 0000898432-23-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.